Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Mesenteric Fibromatosis Mimicking Recurrence after Distal Gastrectomy for Gastric Cancer

  • Kim, Dae-Hoon (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Oh, Seung-Jong (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Oh, Jeong-A (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Bae, Young-Sik (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Choi, Min-Gew (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Noh, Jae-Hyung (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Sohn, Tae-Sung (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Kyoung-Mee (Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Sung (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Bae, Jae-Moon (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2010.05.06
  • Accepted : 2010.06.18
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Mesenteric fibromatosis is a monoclonal, fibroblastic proliferation arising from musculoaponeurotic structure, and it is distinctive lesions defined as a group of non-metastasizing fibroblastic tumors which has local invasion and has a high recurrence rate after the surgical excision. The main treatment modality is the surgical excision. Radiation therapy, chemotherapy, and hormone therapy are also known as useful treatments. We report our experience of a recent case of Mesenteric fibromatosis. A 62-year old female patient had undergone gastrectomy due to gastric cancer. 18 months after gastrectomy, we detected an abdominal mass. The preoperative radiologic findings were suggestive of recurrence. Exploratory laparotomy was performed and post-operative pathologic diagnosis was confirmed as fibromatosis. We report a patient with mesenteric fibromatosis that mimic recurrence after gastrectomy for gastric cancer.

Keywords

References

  1. Allen PW. Th e fi bromatoses: a clinicopathologic classifi cation based on 140 cases. Am J Surg Pathol 1977;1:255-270. https://doi.org/10.1097/00000478-197709000-00007
  2. Dong-Heup K, Kim DH, Goldsmith HS, Quan SH, Huvos AG. Intra-abdominal desmoid tumor. Cancer 1971;27:1041- 1045. https://doi.org/10.1002/1097-0142(197105)27:5<1041::AID-CNCR2820270506>3.0.CO;2-E
  3. Reitamo JJ, Hayry P, Nykyri E, Saxen E. Th e desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the fi nnish population. Am J Clin Pathol 1982;77:665-673. https://doi.org/10.1093/ajcp/77.6.665
  4. Burke AP, Sobin LH, Shekitka KM, Federspiel BH, Helwig EB. Intra-abdominal fibromatosis. A pathologic analysis of 130 tumors with comparison of clinical subgroups. Am J Surg Pathol 1990;14:335-341. https://doi.org/10.1097/00000478-199004000-00004
  5. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25:1785-1791. https://doi.org/10.1200/JCO.2006.10.5015
  6. Reitamo JJ, Scheinin TM, Häyry P. Th e desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986;151:230-237. https://doi.org/10.1016/0002-9610(86)90076-0
  7. Yannopoulos K, Stout AP. Primary solid tumors of the mesentery. Cancer 1963;16:914-927. https://doi.org/10.1002/1097-0142(196307)16:7<914::AID-CNCR2820160708>3.0.CO;2-X
  8. Lynch HT, Fitzgibbons R Jr. Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review. Am J Gastroenterol 1996;91:2598-2601.
  9. Simpson RD, Harrison EG Jr, Mayo CW. Mesenteric fibromatosis in familial polyposis. A variant of Gardner's syndrome. Cancer 1964;17:526-534. https://doi.org/10.1002/1097-0142(196404)17:4<526::AID-CNCR2820170414>3.0.CO;2-Q
  10. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as fi rst-line treatment for desmoid tumors. Cancer 2004;100:612-620. https://doi.org/10.1002/cncr.11937
  11. Brooks AP, Reznek RH, Nugent K, Farmer KC, Th omson JP, Phillips RK. CT appearances of desmoid tumours in familial adenomatous polyposis. Further observations. Clin Radiol 1994;49:601-607. https://doi.org/10.1016/S0009-9260(05)81875-6
  12. Pickhardt PJ, Bhalla S. Unusual nonneoplastic peritoneal and subperitoneal conditions: CT findings. Radiographics 2005;25:719-730. https://doi.org/10.1148/rg.253045145
  13. Lee JC, Thomas JM, Phillips S, Fisher C, Moskovic E. Aggressive fibromatosis: MRI features with pathologic correlation. AJR Am J Roentgenol 2006;186:247-254. https://doi.org/10.2214/AJR.04.1674
  14. Lo KW. Mesenteric fi bromatosis as a potential source of falsepositive interpretation of FDG-PET: report of a case. Dis Colon Rectum 2007;50:924-926. https://doi.org/10.1007/s10350-006-0826-5
  15. Basu S, Nair N, Banavali S. Uptake characteristics of fl uorodeoxyglucose (FDG) in deep fibromatosis and abdominal desmoids: potential clinical role of FDG-PET in the management. Br J Radiol 2007;80:750-756. https://doi.org/10.1259/bjr/53719785
  16. Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. Th e desmoid tumor. Not a benign disease. Arch Surg 1989;124:191-196. https://doi.org/10.1001/archsurg.1989.01410020061010
  17. Spear MA, Jennings LC, Mankin HJ, Spiro IJ, Springfield DS, Gebhardt MC, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998;40:637-645. https://doi.org/10.1016/S0360-3016(97)00845-6
  18. Lahat G, Nachmany I, Itzkowitz E, Abu-Abeid S, Barazovsky E, Merimsky O, et al. Surgery for sporadic abdominal desmoid tumor: is low/no recurrence an achievable goal? Isr Med Assoc J 2009;11:398-402.
  19. Reitamo JJ. The desmoid tumor. IV. Choice of treatment, results, and complications. Arch Surg 1983;118:1318-1322. https://doi.org/10.1001/archsurg.1983.01390110066014
  20. Melis M, Zager JS, Sondak VK. Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol 2008;98:594-602. https://doi.org/10.1002/jso.21033
  21. de Camargo VP, Keohan ML, D'Adamo DR, Antonescu CR, Brennan MF, Singer S, et al. Clinical outcomes of systemic therapy for patients with deep fi bromatosis (desmoid tumor). Cancer 2010;116:2258-2265.
  22. Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24:102-105. https://doi.org/10.1200/JCO.2005.02.1923
  23. Bertagnolli MM, Morgan JA, Fletcher CD, Raut CP, Dileo P, Gill RR, et al. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer 2008;44:2404-2410.
  24. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the eff ect of imatinib on advanced aggressive fi bromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-1203. https://doi.org/10.1200/JCO.2005.04.0717